BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data PR Newswire (Press Release) 20:20 Tue, 19 May
Interstitial Lung Disease May Be Underrecognized in Psoriatic Arthritis Dermatology Advisor 16:29 Tue, 12 May
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults Business Wire (Press Release) 12:07 Fri, 08 May
